GlassScriptPhysician profile
Pablo Hernan Vivas
NPI 1720037690
$3,426.60
in general payments reported to CMS, 2019-2025
19 companies · $483 in 2025
The $483 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $258 · 2021: $938 · 2022: $517 · 2023: $387 · 2024: $354 · 2025: $483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,224.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,268.84 | 2019-2025 | |
| Pfizer INC. | $383.51 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $264.29 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $245.97 | 2020-2023 | Eliquis |
| Boston Scientific Corporation | $225.52 | 2024-2025 | Watchman Flx, General - Therapies |
| Astellas Pharma US INC | $223.14 | 2020-2022 | |
| Abbott Laboratories | $174.42 | 2019-2022 | |
| Esperion Therapeutics, INC. | $106.99 | 2020-2021 | |
| Medtronic, INC. | $103.66 | 2023-2024 | Mycarelink, Micra |
| Sanofi-Aventis U.S. LLC | $83.42 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.66 | 2019-2021 | |
| Edwards Lifesciences Corporation | $70.87 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.82 | 2021-2022 | |
| Heartflow, INC. | $33.24 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $29.99 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $23.77 | 2023 | Inpefa |
| Baxter Healthcare | $19.81 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $14.94 | 2022 | |
| Biotronik INC. | $14.74 | 2024 | Acticor 7 Vr-T Dx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pablo Vivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.